ABSK121

News alerts, weekly reports and conference planners

Company:

Abbisko

Drug class:

pan-FGFR inhib

‹

›

FGFR fusion	Solid Tumor	FGFR fusion	Solid Tumor	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D
FGFR amplification	Solid Tumor	FGFR amplification	Solid Tumor	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D
FGFR mutation	Solid Tumor	FGFR mutation	Solid Tumor	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D

Associations
(3)